Latest Breaking News On - Royalty payment - Page 7 : comparemela.com

The drug maker signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for COVID-19 indication in India. In line with the licensing agreement, Natco Pharma has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for COVID-19 in India. Natco Pharma had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (COSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Eli lillyNatco pharmaIndian patent officeCentral drugs standard control organizationCompulsory licenseCapital marketChemical compoundsHealth sciencesOrganic compoundsBreakthrough therapyEli lilly and companyPharmaceutical industryEli lillyRoyalty paymentHarmaceuticals necCentral drugs